GlassScriptPhysician profile
Nick Gerald Faraci
NPI 1235104662
$2,656.81
in general payments reported to CMS, 2019-2025
23 companies · $597 in 2025
The $597 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $318 · 2021: $458 · 2022: $329 · 2023: $341 · 2024: $285 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $529.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $360.37 | 2022-2025 | Bexsero |
| Sanofi Pasteur INC. | $260.64 | 2019-2025 | |
| Medtronic, INC. | $174.88 | 2021 | |
| Cranial Technologies, INC | $159.18 | 2019-2025 | Doc Band |
| Ars Pharmaceuticals Operations, INC. | $150.12 | 2025 | Neffy |
| Sobi, INC | $144.29 | 2019-2023 | |
| Rhythm Pharmaceuticals, INC. | $125.00 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $123.16 | 2019-2023 | Kristalose |
| Merck Sharp & Dohme LLC | $111.96 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Seqirus USA INC | $82.44 | 2021-2024 | Flucelvax |
| Kowa Pharmaceuticals America, INC. | $81.08 | 2025 | Zoryve |
| Genentech USA, INC. | $74.79 | 2019-2021 | |
| Kaleo, INC. | $60.13 | 2022-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $56.50 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $33.99 | 2021 | |
| Acadia Pharmaceuticals INC | $22.16 | 2025 | Daybue |
| Cipher Pharmaceuticals US LLC | $21.08 | 2025 | Natroba, Spinosad |
| Pharming Healthcare, INC. | $19.89 | 2022 | |
| Aytu Biopharma, INC. | $19.51 | 2024 | Karbinal |
| Verrica Pharmaceuticals INC. | $18.04 | 2024 | Ycanth |
| Abbvie INC. | $14.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Faraci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.